CASE REPORT: New-Onset Autoimmune Thyrotoxicosis with Alemtuzumab Therapy Followed by Rapid Development of Hypothyroidism

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Clinical Thyroidology

• Publication date

  2018-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1089/CT.2018;30.581-584
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Disease

  2020cited by this paper
• Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features

  2018cited by this paper
• Alemtuzumab for the treatment of multiple sclerosis

  2018cited by this paper
• Alemtuzumab, a Monoclonal Antibody to CD52, Frequently Causes Graves’ Disease

  2018cited by this paper
• Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts

  2016cited by this paper
• Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond

  2015cited by this paper
• Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.

  2014cited by this paper
• Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis.

  2014cited by this paper
• Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

  2014cited by this paper
• Alemtuzumab Therapy for Multiple Sclerosis

  2012cited by this paper
• Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

  2012cited by this paper
• Monoclonal antibodies in multiple sclerosis treatment: current and future steps

  2009cited by this paper
• The window of therapeutic opportunity in multiple sclerosis

  2005cited by this paper
• Sclerosis

  2000cited by this paper
• Autoimmune thyroid disease.

  1984cited by this paper

• No citing papers are available for this paper.